Vaccinating against COVID-19 in Allergic Patients

  • Pisuttikan Rangkakulnuwat Department of Pediatrics, School of Medicine, Mae Fah Luang University
Keywords: COVID-19, Anaphylaxis, Allergy, Vaccine


It is over a year since the outbreak of coronavirus (COVID-19) and we are still facing an ongoing pandemic. Whilst the number of infected patients and death rates are increasing everyday, newly developed vaccines are the main hope for humanity to end this misery. From December 2020, emergency authorized vaccines had been distributed to many parts of the world. Studies of the vaccine have confirmed effectiveness with only very rare severe adverse reactions. There are no absolute contraindications for use of the vaccines in people with a history of allergy and preexisting allergic diseases. However, risk assessment and stratification are crucial to ensure ongoing safety for vaccine injection services. The precautions in place for use of the COVID-19 vaccines within high-risk populations include patients with a history of anaphylaxis to previous vaccinations, severe/uncontrolled asthma, and underlying mast cell disorders. These patients should have their vaccine injections under healthcare provider supervision. A consultation with an expert will provide deeper evaluation and shared decision-making for use of the appropriate vaccine. The observation period for the patients with risks of allergic reactions should be at least 15-30 minutes. If anaphylaxis occurs, prompt treatment improves the survival outcomes. Anaphylaxis is a treatable condition without long-term effects. Taking all of this into account, we encourage everybody to join the immunization campaign. Do not let the fear of the reactions outweigh the advantages of being vaccinated.


Download data is not yet available.


World Health Organization. WHO Coronavirus (Covid19) Dashboard. Available from: Access June 2, 2021

National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection. Available from: Access May 28, 2021

Zeng H, Ma Y, Zhou Z, Liu W, Huang P, Jiang M, et al. Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia. Front Med (Lausanne) 2021; 8: 645651.

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27 (7): 1205-11.

Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARSCoV-2 infections and COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397 (10287): 1819-29.

Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021; 397 (10285):1646-57.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383 (27): 2603-15.

Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination hesitancy. BMJ 2021; 373: n1138.

Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun 2021; 94: 41-50.

World Health Organization. Vaccine safety basics [WHO e-learning document]. Available from: Access May29, 2021

Principi N, Esposito S. Adverse events following immunization: real causality and myths. Expert Opin Drug Saf 2016; 15 (6): 825-35.

World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. 2nd ed., 2019 update ed. Geneva: World Health Organization; 2019.

World Health Organization. (2014). Global manual on surveillance of adverse events following immunization, 2016 update. Available from

Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 2021; 6 (1): 28.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397 (10277): 881-91.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396 (10249): 467-78.

World Health Organization. (2021). Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: interim guidance, 7 May 2021. World Health Organization. License: CC BY-NC-SA 3.0 IGO

World Health Organization. (2021). Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, 24 May 2021. World Health Organization. License: CC BY-NC-SA 3.0 IGO

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARSCoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA 2021; 326 (1): 35-45.

Centers for Disease Control and Prevention. COVID-19 Vaccine Quick Reference Guide for Healthcare Professionals 2021. Available from: Access 31 May, 2021

Centers for Disease Control and Prevention COVID-19 Response Team. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14 e 23, 2020. MMWR 2021; 70: 46-51

Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med 2021; 384 (7): 643-9.

Banerji A, Wickner PG, Saff R, Stone CA, Jr., Robinson LB, Long AA, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract 2021; 9 (4): 1423-37.

Caminati M, Guarnieri G, Senna G. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine? Vaccines (Basel) 2021; 9 (1): 38.

Kino Y. [Vaccine excipients]. Nihon Rinsho 2008; 66 (10): 1933-7.

Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines (Basel) 2021; 9 (3): 221.

Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J 2021; 14 (2):100517.

Caballero ML, Quirce S. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines. J Investig Allergol Clin Immunol 2021; 31(1): 92-3.

Stone CA, Jr., Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract 2019; 7 (5):1533-40 e8.

Wheeler AW, Woroniecki SR. Immunological adjuvants in allergy vaccines: Past, present future. Allergol Int 2001; 50 (4): 295-301.

Kutlu A, Ucar R, Aydin E, Arslan S, Caliskaner AZ. Could aluminum be a new hidden allergen in type 1 hypersensitivity reactions when used as a drug additive? Postepy Dermatol Alergol 2016; 33 (3): 243-5.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21 (2): 181-92.

Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 29 April 2021. Available from: (sage)-29-april-2021, accessed 30 May 2021.

Department of disease control (Thailand). Summary of daily vaccination report [Government report document]. Available from: Access 31 May 2021

The allergy, asthma and immunology Association of Thailand (AAIAT). Highlights of Allergy & COVID-19 Vaccine [AAIAT news and events]. Available from:

Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy 2021; 76 (6): 1629-39.

Murphy KR, Patel NC, Ein D, Hudelson M, Kodoth S, Marshall GD, Jr., et al. Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines. Ann Allergy Asthma Immunol. 2021; 126 (4): 319-20.

British Thoracic Society. COVID-19 Vaccination: information for health care professionals [BTS information sheet]. Available from: Access 31 May 2021

Global initiative for asthma. GINA guidance about COVID-19 and asthma [interim guidance Mar 2021]. Available from: Access 31 May 2021

Fineman SM, Bowman SH, Campbell RL, Dowling P, O’Rourke D, Russell WS, et al. Addressing barriers to emergency anaphylaxis care: from emergency medical services to emergency department to outpatient follow-up. Ann Allergy Asthma Immunol 2015; 115 (4): 301-5.

Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. JAMA Dermatol 2021.

Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Available from: Access 2 June 2021

AAAAI COVID-19 Response Task Force Team. Guidance on administration of COVID-19 Vaccines Related to Concerns of Allergic Reactions. Available from: Access 30 May 2021

How to Cite
Rangkakulnuwat, P. (2021). Vaccinating against COVID-19 in Allergic Patients. reater ekong ub-egion edical ournal, 1(3), 125-138. etrieved from
Review Articles